SCHEMBL3597934

SCHEMBL3597934

O=[N+]([O-])c1ccc2c(C(O)(CN3CCCCC3)C(F)(F)F)cn(Cc3ccccc3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNB4 O00305 2/20 0.44
CACNA1A O00555 2/20 0.44
CACNA1G O43497 2/20 0.44
CACNG3 O60359 2/20 0.44
CACNA1F O60840 2/20 0.44
CACNA1H O95180 2/20 0.44
CACNB3 P54284 2/20 0.44
CACNA2D1 P54289 2/20 0.44
CACNG7 P62955 2/20 0.44
CACNA1B Q00975 2/20 0.44
CACNA1D Q01668 2/20 0.44
CACNB1 Q02641 2/20 0.44
CACNG1 Q06432 2/20 0.44
CACNB2 Q08289 2/20 0.44
CACNA1S Q13698 2/20 0.44
CACNA1C Q13936 2/20 0.44
CACNA1E Q15878 2/20 0.44
CACNA2D4 Q7Z3S7 2/20 0.44
CACNA2D3 Q8IZS8 2/20 0.44
CACNG8 Q8WXS5 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594430 0.94 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2LMNAMAPTTDP1
SCHEMBL3598200 0.91 KAT2B (0.38) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL3595274 0.91 HTR7 (0.39) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL13254029 0.91 ALDH1A1 (0.37) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL3603538 0.91 CACNB4 (0.45) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL3600408 0.91 KCNJ1 (0.47) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL3593638 0.91 ACHE (0.41) KMT2AMAPT
SCHEMBL3596441 0.90 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2LMNAMAPTTDP1
Hydrochloric Acid SCHEMBL3593801 0.90 ALDH1A1 (0.37) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL3586209 0.90 ALDH1A1 (0.40) ALDH1A1KMT2ASMN1; SMN2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE NR3C1, NR3C2, NR0B1 CACNB4 2414/4885CACNA1A 2571/4885CACNA1G 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.